激素治疗对晚期子宫内膜癌有效吗?一项系统综述与荟萃分析
该系统综述与荟萃分析纳入39项研究,评估激素治疗晚期子宫内膜癌的疗效。一线激素治疗平均客观缓解率为21.6%,临床获益率36.7%,中位无进展生存期2.8个月、总生存期10.2个月。雌激素受体阳性(26.5%)和孕激素受体阳性(35.5%)肿瘤的客观缓解率更高,受体阴性者较低(9.2%和12.1%)。
要点
- 一线激素治疗晚期子宫内膜癌平均客观缓解率21.6%,临床获益率36.7%。
- 雌激素受体阳性肿瘤客观缓解率26.5%,孕激素受体阳性35.5%,受体阴性者分别为9.2%和12.1%。
- 二线激素治疗客观缓解率18.5%,临床获益率35.8%,且可能受既往激素治疗反应影响。
核心结论
- 激素治疗在晚期子宫内膜癌中与适度的客观缓解率相关,且在激素受体阳性肿瘤中最高。
- 二线治疗的缓解率可能取决于对既往激素治疗的反应。
研究设计与样本
- 系统检索电子数据库,纳入39项激素治疗晚期子宫内膜癌的研究,其中7项提供基于激素受体状态的亚组数据。
- 按单项研究样本量加权合并数据,进行荟萃分析,并分别分析一线和二线激素治疗研究。
- 进行荟萃回归评估临床病理因素对结局的影响。
主要发现
- 一线激素治疗平均客观缓解率为21.6%,临床获益率为36.7%,中位无进展生存期2.8个月,中位总生存期10.2个月。
- 临床试验中客观缓解率为20.4%,观察性研究中为25.3%。
- 客观缓解率在年龄较大、腺鳞癌组织学和高分级肿瘤中较低。
- 雌激素受体阳性肿瘤客观缓解率为26.5%,孕激素受体阳性为35.5%,雌激素受体阴性为9.2%,孕激素受体阴性为12.1%。
- 二线激素治疗客观缓解率为18.5%,临床获益率为35.8%,但临床获益率与一线和二线中稳定疾病评估时机显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormonal therapy (HT) is used commonly in the treatment of advanced endometrial cancer (EC). However, a 2010 Cochrane Review did not show a survival benefit for HT. Here, we quantify its effects and explore the influence of clinico-pathologic factors and hormone receptor (HR) status on overall response rates (ORR). METHODS: A systematic search of electronic databases identified publications of HT in advanced EC. Data from individual studies reporting ORR, median progression-free (PFS) or overall survival (OS) were weighted by individual study sample size and pooled in a meta-analysis. Outcomes of estrogen (ER) and progesterone receptor (PgR) subgroups were collected. Studies of first- and second-line HT were analyzed independently. Mixed studies were included if subgroup data based on previous HT exposure were provided. Meta-regression was performed to evaluate the influence of clinico-pathologic factors on outcomes. RESULTS: Thirty-nine studies were included, with seven providing subgroup data based on HR status. First-line HT was associated with a mean ORR of 21.6% and clinical benefit rate (CBR) of 36.7%. Median PFS and OS were 2.8 and 10.2months respectively. ORR was 20.4% in clinical trials and 25.3% in observational studies. Magnitude of ORR was lower in older age, adenosquamous histology and high grade. ORR was higher in ER+ (26.5%) and PgR+ (35.5%) disease, and lower in ER- (9.2%) or PgR- (12.1%) tumors. Second-line ORR was 18.5%. CBR was 35.8%, but was significantly associated with timing of stable disease assessments in first- and second-line. Meta-regression performed in mixed and second-line studies showed an association between previous HT and greater ORR (β 0.561; p=0.024), suggesting potential confounding by indication (re-treatment of good responders to first-line HT). CONCLUSION: HT is associated with modest ORR in advanced EC, and is greatest in HR+ tumors. Response rates in second-line are likely dependent on response to previous HT.
引用
- Ethier JL, Desautels DN, Amir E, et al. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol. 2017. PMID: 28689667. doi:10.1016/j.ygyno.2017.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。